Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro

Q: What type of study is this?

This is a In Vitro Study study.

Dong Yong; Zhidong Hu

doi:10.1186/s12866-025-04554-8

December 2, 2025BMC MicrobiologyOpen Access

Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro

View Full Paper

Ask AI

Bookmark

Share

Key Points

In vitro analysis shows enhanced antibacterial activity of combined drugs against Klebsiella pneumoniae.
Key evidence includes the effectiveness of Tigecycline and Polymyxin B in overcoming heteroresistance.
Assessment using combined drugs against antibiotic-resistant pathogens highlights the need for improved therapies.
This research suggests potential improvements for clinical treatments targeting heteroresistant infections.

Implication

In vitro analysis reveals antibacterial activity of Tigecycline and Polymyxin B against heterogeneous Klebsiella pneumoniae, suggesting enhanced treatment options.

Abstract

This study provides valuable insights and theoretical support for the clinical therapy of relevant heteroresistance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yong et al. (2025) studied this question.

synapsesocial.com/papers/69337cceb3f947a0a1259be6 https://doi.org/10.1186/s12866-025-04554-8

View Full Paper

Ask AI

Bookmark

Share

Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro

Key Points

Implication

Abstract

Discussion

Cite This Study

Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading